An initiative aimed at entering the biopharmaceutical CDMO business through an investment in Renzoku, leveraging fully continuous manufacturing technology for antibody drugs. The initiative will combine this with the technical and operational expertise of the existing EMS business to improve production and cost efficiency through variable-scale production, the ability to handle small-volume, high-mix manufacturing, automation, and data utilization.